Study #PA18-1100
Biomarker discovery study of DS-8201a, an anti-HER2-antibody drug conjugate, in randomized phase III trials (DS8201-A-U301, U302, U303) in unresectable and/or metastatic breast cancer and in patients receiving DS-8201 as standard of care treatment
MD Anderson Study Status
Enrolling
Treatment Agent
Description
Biomarker study of DS-8201a in phase iii trials
Resources and Links
Phone Number: 1-877-MDA-6789
clinicaltrials.gov NCT No: N/A
Information and next steps
Disease:
Study phase:
Not applicable
Physician name:
Azadeh Nasrazadani
Department:
Breast Medical Oncology
For general questions about clinical trials:
1-855-371-6974
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.